Interindividual variability in inhibition and induction of cytochrome P450 enzymes

被引:194
作者
Lin, JH [1 ]
Lu, AYH
机构
[1] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA
[2] Rutgers State Univ, Coll Pharm, Canc Res Lab, Piscataway, NJ 08854 USA
关键词
quantitative prediction of drug interactions; intestinal first-pass metabolism; genetic polymorphism; drug interactions;
D O I
10.1146/annurev.pharmtox.41.1.535
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Drug interactions have always been a major concern in medicine for clinicians and patients. Inhibition and induction of cytochrome P450 (CYP) enzymes are probably the most common causes for documented drug interactions. Today, many pharmaceutical companies are predicting potential interactions of new drug candidates. Can in vivo drug interactions be predicted accurately from in vitro metabolic studies? Should the prediction be qualitative or quantitative? Although some scientists believe that quantitative prediction of drug interactions is possible, others are less optimistic and believe that quantitative prediction would be very difficult. There are many factors that contribute to our inability to quantitatively predict drug interactions. One of the major complicating factors is the large interindividual variability in response to enzyme inhibition and induction. This review examines the sources that are responsible for the interindividual variability in inhibition and induction of cytochrome P450 enzymes.
引用
收藏
页码:535 / 567
页数:33
相关论文
共 136 条
[1]
ALVAN G, 1977, CLIN PHARMACOL THER, V22, P316
[2]
EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[3]
[Anonymous], PHARMACOGENETICS DRU
[4]
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[5]
BACK D J, 1987, Alimentary Pharmacology and Therapeutics, V1, P339
[6]
Rifampin drastically reduces plasma concentrations and effects of oral midazolam [J].
Backman, JT ;
Olkkola, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :7-13
[7]
Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice [J].
Bailey, DG ;
Bend, JR ;
Arnold, JMO ;
Tran, LT ;
Spence, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :25-33
[8]
Grapefruit juice felodipine interaction:: Effect of naringin and 6′,7′-dihydroxybergamottin in humans [J].
Bailey, DG ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :248-256
[9]
INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE [J].
BAILEY, DG ;
SPENCE, JD ;
MUNOZ, C ;
ARNOLD, JMO .
LANCET, 1991, 337 (8736) :268-269
[10]
BARBARASH R A, 1987, Drug Intelligence and Clinical Pharmacy, V21, p11A